Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Manhattan Eye, Ear & Throat Hospital |
---|---|
Information provided by: | Manhattan Eye, Ear & Throat Hospital |
ClinicalTrials.gov Identifier: | NCT00211445 |
Central serous choroidal (CSC) retinopathy is a disease of the macula characterized by exudation of fluid under the retina localized to the posterior pole as well as loss of vision. The etiology is unknown, but according to the studies this condition is more common in young males and is associated with type A personality. Clinically, CSC is characterized by serous retinal detachment and area of leakage of in the subretinal space. The standard of care for acute CSC is observation for a period of up to 3 months. If there is no complete resolution of the retinal detachment by 3 months, there is an indication for focal laser photocoagulation therapy of the area of leakage. This treatment is usually effective in stopping leakage of fluid under the retina and causing resolution of detachment. However, laser photocoagulation therapy is not beneficial in the treatment of chronic CSC because there is not a single easily identifiable point of leakage but rather diffuse disease of RPE thus rendering laser treatment ineffective.The purpose of this medical research study is to evaluate Verteporfin therapy as an approach which may benefit patients with CSC, based on observations in exudative type of AMD patients treated with Photodynamic Therapy using Verteporfin.
Condition | Intervention | Phase |
---|---|---|
Chronic Central Serous Chorioretinopathy |
Procedure: Photodynamic Therapy with Verteporfin Drug: verteporfin Drug: Verteporfin |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Enrollment: | 11 |
Study Start Date: | July 2002 |
Study Completion Date: | January 2006 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, New York | |
Manhattan Eye, Ear & Throat Hospital | |
New York, New York, United States, 10021 |
Principal Investigator: | Jason S. Slakter, MD | Manhattan Eye, Ear & Throat Hospital |
Study ID Numbers: | PDT for CSC |
Study First Received: | September 13, 2005 |
Last Updated: | September 27, 2007 |
ClinicalTrials.gov Identifier: | NCT00211445 |
Health Authority: | United States: Institutional Review Board |
Verteporfin Central serous chorioretinopathy |
Photosensitizing Agents Radiation-Sensitizing Agents Therapeutic Uses |
Physiological Effects of Drugs Dermatologic Agents Pharmacologic Actions |